Navigation Links
Breast Cancer Message Barred in Eli Lilly's Hometown
Date:11/3/2010

SAN FRANCISCO, Nov. 3, 2010 /PRNewswire-USNewswire/ --Breast Cancer Action (BCA) learned today that its efforts to deliver a message to Eli Lilly & Company via a billboard in Indianapolis have been blocked.  The message:  "Eli Lilly is making us sick.  Tell them to stop" was rejected by every billboard company in Indianapolis, Lilly's hometown.

Despite working within the guidelines of each billboard company contacted, the advocacy group has been turned down because of the content of the message.  At a time when political advertizing across the nation has reached an all time high, the rejection of BCA's message raises critical questions about who controls the media when it comes to public health.

"We are talking about women's health here.  A breast cancer organization's message about the impact of a drug company's behavior is being kept off billboards in the company's home town.  When corporate influence runs this deep, the public should be outraged. We certainly are," said BCA executive director Barbara Brenner.

The public's health is at stake.  Eli Lilly is the sole worldwide manufacturer of rBGH (recombinant bovine growth hormone also known as rBST) which is sold under the name Posilac and has long been linked to cancer.  The artificial hormone is given to dairy cows to stimulate milk production.

Breast Cancer Action's "Milking Cancer" campaign demands Eli Lilly stop manufacturing the artificial stimulant rBGH.  In September 2010, signatures were gathered from over 6,732 individuals—one for each day that rBGH has been on the market—committed to delivering a message to Eli Lilly via a billboard in Indianapolis. For more information see www.milkingcancer.org.

Breast Cancer Action is a non-profit education and advocacy organization that does not accept funding from pharmaceutical companies or any other organizations that profit from or contribute to the breast cancer epidemic.


'/>"/>
SOURCE Breast Cancer Action
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CyberKnife Radiosurgery for Early-Stage Breast Cancer
2. 10 Tips for Breast Cancer Survivors
3. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
4. 10 Tips for Breast Cancer Screening and Early Detection
5. Jefferson Radiology Becomes First Diagnostic Imaging Group in Connecticut to Add Automated Ultrasound Capability for Screening Women with Dense Breast Tissue
6. Alma Lasers Joins the Fight Against Breast Cancer with the Launch of the NEW SopranoXLi
7. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
8. FUJIFILM Revitalizes Images of Health Breast Cancer Awareness Initiative
9. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
Breaking Medicine News(10 mins):